FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129783860> ?p ?o ?g. }

• W2129783860 endingPage "4457" @default.
• W2129783860 startingPage "4452" @default.
• W2129783860 abstract "Abstract Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m2 per week) dosed on weeks 2 to 5 and 13 to 16. Twenty-five patients were enrolled, 20 of whom were untreated. Responses were complete response (n = 1), partial response (n = 15), and major response (n = 2), for overall and major response rate of 72% and 64%, respectively, on an intent-to-treat basis. Median serum IgM decreased from 3670 to 1590 mg/dL (P < .001), whereas median hematocrit rose from 33.0% to 37.6% (P = .004) at best response. Median time to progression for responders was 38 months. Peripheral neuropathy to thalidomide was the most common adverse event. Among 11 patients experiencing grade 2 or greater neuropathy, 10 resolved to grade 1 or less at a median of 6.7 months. Thalidomide in combination with rituximab is active and produces long-term responses in WM. Lower doses of thalidomide (ie, ≤ 200 mg/day) should be considered given the high frequency of treatment-related neuropathy in this patient population. This trial is registered at www.clinicaltrials.gov as #NCT00142116." @default.
• W2129783860 created "2016-06-24" @default.
• W2129783860 creator A5000713282 @default.
• W2129783860 creator A5003794686 @default.
• W2129783860 creator A5009941507 @default.
• W2129783860 creator A5013443247 @default.
• W2129783860 creator A5026121534 @default.
• W2129783860 creator A5031106919 @default.
• W2129783860 creator A5032177345 @default.
• W2129783860 creator A5032464400 @default.
• W2129783860 creator A5034484462 @default.
• W2129783860 creator A5035601705 @default.
• W2129783860 creator A5038147464 @default.
• W2129783860 creator A5047642604 @default.
• W2129783860 creator A5051866927 @default.
• W2129783860 creator A5052348131 @default.
• W2129783860 creator A5055840262 @default.
• W2129783860 creator A5055972238 @default.
• W2129783860 creator A5063283496 @default.
• W2129783860 creator A5076009353 @default.
• W2129783860 creator A5076758699 @default.
• W2129783860 creator A5081299017 @default.
• W2129783860 creator A5082789503 @default.
• W2129783860 creator A5087587888 @default.
• W2129783860 creator A5088343926 @default.
• W2129783860 creator A5090361137 @default.
• W2129783860 creator A5091691031 @default.
• W2129783860 date "2008-12-01" @default.
• W2129783860 modified "2023-10-12" @default.
• W2129783860 title "Thalidomide and rituximab in Waldenstrom macroglobulinemia" @default.
• W2129783860 cites W1590344479 @default.
• W2129783860 cites W1910831415 @default.
• W2129783860 cites W1924027236 @default.
• W2129783860 cites W1945251789 @default.
• W2129783860 cites W1972632013 @default.
• W2129783860 cites W1976156505 @default.
• W2129783860 cites W1984207121 @default.
• W2129783860 cites W1996373638 @default.
• W2129783860 cites W1997487298 @default.
• W2129783860 cites W2012570443 @default.
• W2129783860 cites W2012959199 @default.
• W2129783860 cites W2022765648 @default.
• W2129783860 cites W2032454178 @default.
• W2129783860 cites W2044360617 @default.
• W2129783860 cites W2072685911 @default.
• W2129783860 cites W2099365933 @default.
• W2129783860 cites W2100593237 @default.
• W2129783860 cites W2109587991 @default.
• W2129783860 cites W2109638333 @default.
• W2129783860 cites W2117582823 @default.
• W2129783860 cites W2118006412 @default.
• W2129783860 cites W2119810076 @default.
• W2129783860 cites W2128792612 @default.
• W2129783860 cites W2129664415 @default.
• W2129783860 cites W2131252187 @default.
• W2129783860 cites W2132155614 @default.
• W2129783860 cites W2137296394 @default.
• W2129783860 cites W2149103702 @default.
• W2129783860 cites W2149287539 @default.
• W2129783860 cites W2150724746 @default.
• W2129783860 cites W2165172574 @default.
• W2129783860 cites W2556583364 @default.
• W2129783860 doi "https://doi.org/10.1182/blood-2008-04-150854" @default.
• W2129783860 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2597120" @default.
• W2129783860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18713945" @default.
• W2129783860 hasPublicationYear "2008" @default.
• W2129783860 type Work @default.
• W2129783860 sameAs 2129783860 @default.
• W2129783860 citedByCount "126" @default.
• W2129783860 countsByYear W21297838602012 @default.
• W2129783860 countsByYear W21297838602013 @default.
• W2129783860 countsByYear W21297838602014 @default.
• W2129783860 countsByYear W21297838602015 @default.
• W2129783860 countsByYear W21297838602016 @default.
• W2129783860 countsByYear W21297838602017 @default.
• W2129783860 countsByYear W21297838602018 @default.
• W2129783860 countsByYear W21297838602019 @default.
• W2129783860 countsByYear W21297838602020 @default.
• W2129783860 countsByYear W21297838602021 @default.
• W2129783860 countsByYear W21297838602022 @default.
• W2129783860 crossrefType "journal-article" @default.
• W2129783860 hasAuthorship W2129783860A5000713282 @default.
• W2129783860 hasAuthorship W2129783860A5003794686 @default.
• W2129783860 hasAuthorship W2129783860A5009941507 @default.
• W2129783860 hasAuthorship W2129783860A5013443247 @default.
• W2129783860 hasAuthorship W2129783860A5026121534 @default.
• W2129783860 hasAuthorship W2129783860A5031106919 @default.
• W2129783860 hasAuthorship W2129783860A5032177345 @default.
• W2129783860 hasAuthorship W2129783860A5032464400 @default.
• W2129783860 hasAuthorship W2129783860A5034484462 @default.
• W2129783860 hasAuthorship W2129783860A5035601705 @default.
• W2129783860 hasAuthorship W2129783860A5038147464 @default.
• W2129783860 hasAuthorship W2129783860A5047642604 @default.
• W2129783860 hasAuthorship W2129783860A5051866927 @default.
• W2129783860 hasAuthorship W2129783860A5052348131 @default.
• W2129783860 hasAuthorship W2129783860A5055840262 @default.
• W2129783860 hasAuthorship W2129783860A5055972238 @default.
• W2129783860 hasAuthorship W2129783860A5063283496 @default.

• next